癌症免疫疗法开发商Nouscom筹集1.2亿欧元D轮融资，将在欧洲肿瘤内科学会年会（ESMO）公布林奇综合征携带者癌症长期早筛阻断临床数据-动脉网

Nouscom Raises €120 Million ($135 Million) in Oversubscribed Series D Financing and will Present Long-Term Cancer Interception Clinical Data in Lynch Syndrome Carriers at ESMO

GlobeNewswire 等信源发布 2026-10-19 06:00



可切换为仅中文







Oversubscribed €120 million Series D financing was led by M Ventures and Revelation Partners, with new investors Angelini Industries, the European Investment Bank and Neva SGR and participation from all existing investors.

超额认购的1.2亿欧元D轮融资由M Ventures和Revelation Partners领投，新投资者包括Angelini Industries、欧洲投资银行和Neva SGR，所有现有投资者也参与了跟投。

Proceeds will fund advancement of Nouscom’s lead asset NOUS-209, an investigational, off-the-shelf neoantigen-based cancer immunotherapy, through a global, registration-enabling clinical trial for cancer interception in Lynch Syndrome (LS) carriers.

所得资金将用于推进 Nouscom 公司的核心资产 NOUS-209 的研发，这是一种在研的、现成的基于新抗原的癌症免疫疗法，旨在通过一项全球性的、支持注册申请的临床试验，用于林奇综合征（LS）携带者的癌症拦截。

Long-term cancer interception data from Phase 1b/2 trial of NOUS-209 in LS carriers will be presented at European Society of Medical Oncology (ESMO).

在林奇综合征携带者中开展的NOUS-209的1b/2期试验的长期癌症拦截数据将在欧洲肿瘤内科学会（ESMO）上公布。

BASEL, Switzerland – October 19, 2026 –

瑞士巴塞尔 – 2026年10月19日 –

Nouscom, a clinical-stage, cancer interception focused biotech developing next-generation immunotherapies, today announced the closing of an oversubscribed €120 million ($135 million) Series D financing. The round was co-led by M Ventures and Revelation Partners alongside new investors Angelini Industries (through Angelini Investments), the European Investment Bank (through Aurea, its co-investment facility with Angelini Ventures), and Neva SGR (Intesa Sanpaolo Group).

专注于癌症拦截、处于临床阶段并开发下一代免疫疗法的生物科技公司 Nouscom 今日宣布完成一轮超额认购的 1.2 亿欧元（1.35 亿美元）D 轮融资。本轮融资由 M Ventures 和 Revelation Partners 共同领投，新投资者包括 Angelini Industries（通过 Angelini Investments）、欧洲投资银行（通过其与 Angelini Ventures 的联合投资工具 Aurea）以及 Neva SGR（Intesa Sanpaolo 集团）。

Nouscom’s other existing international life sciences investors, 5AM Ventures, Andera Partners, Angelini Ventures, Bpifrance (through its InnoBio2 fund), CDP Venture Capital (through its Large Ventures Fund), EQT Life Sciences, Indaco Venture Partners, Panakes Partners, Versant Ventures and XGEN Ventures, all participated in the round.

Nouscom的其他现有国际生命科学领域投资者，包括5AM Ventures、Andera Partners、Angelini Ventures、法国公共投资银行Bpifrance（通过其InnoBio2基金）、意大利CDP风险资本（通过其Large Ventures Fund）、EQT Life Sciences、Indaco Venture Partners、Panakes Partners、Versant Ventures以及XGEN Ventures，均参与了本轮融资。

The strong demand for the round reflects investor conviction in Nouscom’s pipeline and recently published clinical data..

本轮强劲的需求反映了投资者对Nouscom产品管线及近期发布的临床数据的信心。

Proceeds from the Series D round will fund the advancement of NOUS-209, an investigational off-the-shelf neoantigen-based cancer immunotherapy, through a single, global, registration-enabling clinical trial for cancer interception in Lynch Syndrome (LS) carriers, for which FDA has granted Fast Track designation..

D轮融资所得款项将用于推进NOUS-209的研发，这是一种在研的现成型新抗原癌症免疫疗法。公司将通过一项单一的全球性注册临床试验，评估该疗法在林奇综合征（LS）携带者中的癌症拦截效果，美国食品药品监督管理局（FDA）已授予其快速通道资格。

The financing coincides with a presentation of long-term cancer interception data from a Phase 1b/2 trial of NOUS-209 in LS carriers, to be presented at the European Society of Medical Oncology (ESMO) Congress by the study’s principal investigator Eduardo Vilar-Sanchez, M.D., Ph.D., chair ad interim of Clinical Cancer Prevention at The University of Texas MD Anderson Cancer Center.

此次融资恰逢公布NOUS-209在Lynch综合征（LS）携带者中开展的1b/2期临床试验的长期癌症拦截数据，该数据将由本研究的主要研究者、德克萨斯大学MD安德森癌症中心临床癌症预防临时主席Eduardo Vilar-Sanchez医学博士、哲学博士在欧洲肿瘤内科学会（ESMO）大会上发表。

ESMO is taking place in Madrid, Spain on 23-27 October 2026. Details of the presentation are below..

欧洲肿瘤内科学会（ESMO）会议将于2026年10月23日至27日在西班牙马德里举行。演讲详情如下。

The abstract, published by ESMO, reports that all evaluable LS carriers dosed with NOUS-209 remained free of advanced adenomas and colorectal cancer, as determined by colonoscopy, after years 1 and 2 (n=43; n=17, respectively), representing an encouraging signal of durable clinical activity consistent with a treatment effect relative to the expected incidence in LS carriers.

由欧洲肿瘤内科学会（ESMO）发布的摘要报告称，所有接受NOUS-209给药的可评估林奇综合征（LS）携带者在第1年和第2年（分别为n=43和n=17）后，经结肠镜检查确认均未出现进展性腺瘤和结直肠癌，这一结果呈现出令人鼓舞的持久临床活性信号，与相对于林奇综合征携带者预期发病率的治疗效应一致。

These data were strengthened by broad, potent, and durable anti-neoantigen T-cell responses driven by NOUS-209 that were further enhanced following annual re-treatment..

这些数据的可靠性得到了进一步证实，因为NOUS-209引发了广泛、强效且持久的抗新抗原T细胞反应，并且在每年重复治疗后进一步增强。

“

Over two million LS carriers live with up to an 80% lifetime cancer risk and nothing to offer them but surveillance and surgery

超过两百万林奇综合征携带者面临高达80%的终生癌症风险，而目前除了监测和手术外，别无其他干预手段可供提供。

”, said

”，说道

Marina Udier, Ph.D., Chief Executive Officer of Nouscom

玛丽娜·乌迪尔博士，Nouscom 首席执行官

。

“We built Nouscom to change that equation. This financing, alongside the data we are presenting at ESMO, puts us closer to a world where cancer is stopped before it starts. I am grateful to our new and existing investors for backing that conviction, and to the team behind NOUS-209.”

“我们创立Nouscom旨在改变这一局面。此次融资，连同我们在ESMO大会上展示的数据，使我们更接近于在癌症发生之前就将其遏制的世界。我感谢新老投资者对这一信念的支持，也感谢NOUS-209背后的团队。”

“This significant financing reflects the confidence of our investors in Nouscom’s vision, team and the transformative potential of cancer interception,”

“这笔重要的融资反映了投资者对Nouscom的愿景、团队以及癌症拦截变革潜力的信心，”

said

说

Göran Ando, M.D., Independent Chair of the Board of Nouscom

Göran Ando 医学博士，Nouscom 董事会独立主席

。

“With this backing, we are well positioned to accelerate NOUS-209’s clinical development and our commitment to those living with Lynch Syndrome. I am delighted to welcome our new investors, whose support further strengthens Nouscom as we enter this next chapter.”

“在此支持下，我们处于有利地位，能够加速NOUS-209的临床开发，并履行我们对林奇综合征患者的承诺。我很高兴欢迎我们的新投资者，他们的支持在我们进入这一新篇章之际进一步增强了Nouscom的实力。”

Dr. Hakan Goker, Managing Director and Head of Biotechnology Investments at M Ventures

M Ventures 的董事总经理兼生物技术投资主管 Hakan Goker 博士

, said: “

，说：“

What sets Nouscom apart is its unique cancer interception approach and the platform that enables it. Maturing clinical evidence and a regulatory-aligned path into a registration-enabling trial in such an unchartered space is a rare combination for a private biotech company and the commitment of the investor syndicate underpins this deep conviction.

Nouscom 的与众不同之处在于其独特的癌症拦截方法以及支撑该方法的平台。对于一家私营生物科技公司而言，日益成熟的临床证据以及在如此未知的领域中符合监管要求的注册性试验路径是一种罕见的组合，而投资者财团的承诺则坚定了这一深层信念。

.”

。”

Angelini Industries joins as a new investor, having followed Nouscom since its Series C round through Angelini Ventures, which also participated in the Series D.

Angelini Industries 作为新投资者加入，自 Nouscom C 轮融资以来一直通过 Angelini Ventures 对其进行跟踪投资，后者也参与了 D 轮融资。

'Angelini Industries is becoming an increasingly innovation-driven group competing on a global scale, bringing together the search for companies set to shape the future of healthcare with the research and pharmaceutical assets of our industrial heritage.”

“安吉里尼工业集团正日益成为一个以创新为驱动、在全球范围内展开竞争的集团，将发掘有望塑造医疗健康未来的企业与我们的工业遗产所蕴含的研发和制药资产相结合。”

said

说

Sergio Marullo di Condojanni, Chief Executive Officer of Angelini Industries, and VP of Angelini Investments

Sergio Marullo di Condojanni，Angelini Industries 首席执行官兼 Angelini Investments 副总裁

。

“We see significant potential in Nouscom’s pioneering approach to cancer prevention in Lynch Syndrome and we are proud to support its outstanding team.”

“我们看到Nouscom在Lynch综合征癌症预防方面的开创性方法具有巨大的潜力，并为支持其卓越的团队而感到自豪。”

Details of the Presentation:

演示详情：

Title: Safety and Immunogenicity of Re-vaccination with Nous-209: a neoantigen vaccine for cancer interception in Lynch syndrome carriers

标题：Nous-209再接种的安全性和免疫原性：一种用于林奇综合征携带者癌症拦截的新抗原疫苗

Presenter: Eduardo Vilar-Sanchez, M.D., Ph.D., The University of Texas MD Anderson Cancer Center

演讲者：Eduardo Vilar-Sanchez，医学博士、哲学博士，德克萨斯大学 MD 安德森癌症中心

Abstract #: 3438O

摘要编号：3438O

Date/Time: Sunday 25 October, 15:15hrs CEST

日期/时间：10月25日星期日，中欧夏令时15:15

Location: Granada Auditorium, Hall 4

地点：格拉纳达礼堂，4号厅

The Phase 1b/2 clinical trial of NOUS-209 in LS carriers (NCT05078866) was a collaborative effort between the National Cancer Institute’s Cancer Prevention Clinical Trials Network (

NOUS-209在LS携带者中的1b/2期临床试验（NCT05078866）是美国国家癌症研究所癌症预防临床试验网络（

CP-CTNet

) and the iCAN-PREVENT consortium at UT MD Anderson. The NCI, part of the National Institutes of Health, provided primary funding through Award Number UG1-CA-242609, with additional support from the Data Management, Auditing, and Coordination Center (grant U24CA242637).

）以及德克萨斯大学 MD 安德森癌症中心的 iCAN-PREVENT 联盟。美国国家癌症研究所（NCI，隶属于美国国立卫生研究院）通过项目编号 UG1-CA-242609 提供了主要资助，数据管理、审计与协调中心（项目编号 U24CA242637）提供了额外支持。

–––

———

About NOUS-209

关于 NOUS-209

NOUS-209 is an investigational off-the-shelf cancer immunotherapy that targets tumors with mismatch repair deficiency (dMMR) and microsatellite instability (MSI). These tumors are characterized by unique markers known as frameshift peptide (FSP) neoantigens, which are unique to cancerous cells and absent in healthy cells.

NOUS-209 是一种在研的现成型癌症免疫疗法，靶向错配修复缺陷（dMMR）和微卫星不稳定性（MSI）肿瘤。这些肿瘤的特征是存在独特的标志物，即移码肽（FSP）新抗原，这类新抗原为癌细胞所特有，而在健康细胞中不存在。

NOUS-209 comprises two proprietary viral vectors able to deliver 209 shared FSP neoantigens and train the immune system to recognize and attack cancerous and precancerous cells before tumors can develop..

NOUS-209 包含两种专有病毒载体，能够递送 209 种共享的 FSP 新抗原，并训练免疫系统在肿瘤形成之前识别并攻击癌变细胞和癌前细胞。

Phase 1b/2 data demonstrated the safety of NOUS-209 and its ability to stimulate potent immune responses in LS carriers

1b/2期数据证明了NOUS-209的安全性及其在LS携带者中激发强效免疫反应的能力

1,2

, supporting its advancement into a registration-enabling trial in cancer interception. NOUS-209 is also being studied in Phase 2 studies in combination with pembrolizumab in a difficult-to-treat patient population of advanced dMMR and/or MSI-H metastatic CRC (mCRC) patients refractory to anti-PD-1 therapy.

，支持其推进至旨在注册的癌症拦截临床试验。NOUS-209 也在与帕博利珠单抗联合使用的 II 期研究中接受评估，针对的是对 PD-1 抑制剂治疗耐药的晚期 dMMR 和/或 MSI-H 转移性结直肠癌（mCRC）这一难治性患者人群。

and in first-line treatment of advanced dMMR and/or MSI-H mCRC. Data from the successfully completed Phase 1b trial were published in

并用于晚期dMMR和/或MSI-H mCRC的一线治疗。已完成的1b期临床试验数据发表于

Science Translational Medicine

《科学·转化医学》

。

About Lynch Syndrome

关于林奇综合征

Lynch Syndrome (LS) is a common inherited condition that significantly increases a person’s risk of developing cancer over their lifetime, especially colorectal cancer (CRC) (up to 50% risk, compared to 2% for general population), endometrial cancer (up to 50% risk, compared to 1-2% for general population) and urothelial cancer (up to 25% risk, compared to 1-2% for general population).

林奇综合征（LS）是一种常见的遗传性疾病，会显著增加个体终生患癌风险，尤其是结直肠癌（CRC）（风险高达50%，而普通人群为2%）、子宫内膜癌（风险高达50%，而普通人群为1-2%）和尿路上皮癌（风险高达25%，而普通人群为1-2%）。

5,6,7,8

. LS also elevates the risk of developing other cancers including biliary tract, brain, duodenal, gastric, Muir-Torre spectrum, ovarian, prostate, pancreatic and small bowel cancer. LS is caused by inherited mutations in specific genes responsible for repairing DNA, leading to the buildup of harmful genetic errors that can accumulate, triggering the development of tumors.

林奇综合征（LS）还增加了罹患其他癌症的风险，包括胆道癌、脑癌、十二指肠癌、胃癌、Muir-Torre 综合征相关癌症、卵巢癌、前列腺癌、胰腺癌和小肠癌。林奇综合征由负责修复 DNA 的特定基因的遗传性突变引起，导致有害的基因错误不断累积，从而引发肿瘤的发生。

Currently, managing LS is limited to frequent screenings such as colonoscopy to catch cancer early, but is not shown to reduce cancer incidence.

目前，林奇综合征（LS）的管理仅限于通过结肠镜检查等频繁筛查来早期发现癌症，但尚未显示能降低癌症发病率。

, and elective surgery, which is invasive, expensive, and negatively impacts quality of life. As a pioneering approach to cancer interception, Nouscom’s investigational immunotherapy, NOUS-209, is designed to train the immune system to recognize and stop cancer before it develops.

以及择期手术，这类手术具有侵入性、费用高昂，且会对生活质量产生负面影响。作为癌症拦截的前沿方法，Nouscom 公司的在研免疫疗法 NOUS-209 旨在训练免疫系统在癌症发展之前识别并阻止其发生。

About Cancer Interception

关于癌症拦截

Cancer interception is an innovative approach that aims to stop cancer in its earliest stages before tumors fully develop and spread. Unlike traditional therapies that target established cancers, interception strategies harness advancements in immuno-oncology that can train the immune system to recognize and eliminate precancerous and cancerous cells.

癌症拦截是一种创新方法，旨在在肿瘤完全发展和扩散之前的最早阶段阻止癌症。与针对已确立癌症的传统疗法不同，拦截策略利用免疫肿瘤学的最新进展，训练免疫系统识别并清除癌前细胞和癌细胞。

This approach is particularly relevant for those with high-risk genetic conditions such as LS who have high predisposition to developing MSI-associated cancers..

这种方法对于患有林奇综合征（LS）等高风险遗传性疾病、且具有高度易感性发生微卫星不稳定性（MSI）相关癌症的人群尤为相关。

About Nouscom

关于 Nouscom

Nouscom is a clinical-stage biotech company pioneering next-generation neoantigen-targeted immunotherapies to treat cancer at all stages, from early cancer interception to late-stage metastatic disease. Its proprietary viral vector platform enables broad and durable immune activation by delivering optimized neoantigens that train the immune system to recognize and fight cancer.

Nouscom 是一家处于临床阶段的生物科技公司，致力于开创下一代靶向新抗原的免疫疗法，用于治疗从早期癌症拦截到晚期转移性疾病的所有阶段癌症。其专有的病毒载体平台通过递送优化的新抗原来训练免疫系统识别并对抗癌症，从而实现广泛而持久的免疫激活。

Nouscom’s lead program, NOUS-209, is an off-the-shelf immunotherapy in advanced clinical development for cancer interception in LS and the treatment of MSI mCRC. The company’s clinical stage portfolio also includes NOUS-PEV, a personalized neoantigen immunotherapy, with published data from a successfully completed Phase 1b trial.

Nouscom的核心项目NOUS-209是一款现成的免疫疗法，正处于晚期临床开发阶段，用于林奇综合征（LS）的癌症拦截以及微卫星不稳定性高转移性结直肠癌（MSI mCRC）的治疗。该公司的临床阶段产品组合还包括NOUS-PEV，一种个性化的新抗原免疫疗法，其已完成的一项1b期临床试验的成功数据已公开发表。

. Nouscom’s current investors include 5AM Ventures, Andera Partners, Angelini Industries (through Angelini Investments), Angelini Ventures, Bpifrance (through its InnoBio2 fund), CDP Venture Capital (through its Large Ventures Fund), EQT Life Sciences, European Investment Bank (through Aurea, its co-investment facility with Angelini Ventures), Indaco Venture Partners SGR, M Ventures, Neva SGR (Intesa Sanpaolo Group), Panakes Partners, Revelation Partners, Versant Ventures and XGEN Ventures..

Nouscom 的现有投资者包括：5AM Ventures、Andera Partners、Angelini Industries（通过 Angelini Investments）、Angelini Ventures、法国公共投资银行 Bpifrance（通过其 InnoBio2 基金）、CDP Venture Capital（通过其 Large Ventures Fund）、EQT Life Sciences、欧洲投资银行（通过 Aurea，即其与 Angelini Ventures 的联合投资平台）、Indaco Venture Partners SGR、M Ventures、Neva SGR（意大利联合圣保罗银行集团）、Panakes Partners、Revelation Partners、Versant Ventures 以及 XGEN Ventures。

For more information on Nouscom, please visit the company’s website at

如需了解更多关于 Nouscom 的信息，请访问公司网站：

www.nouscom.com

or follow us on

或在以下平台关注我们

领英

。

References

参考文献

D’Alise, AM.

达利塞，A.M.

et al